Tumor Biology

, Volume 37, Issue 8, pp 10427–10433 | Cite as

The clinical and prognostic significance of CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy

  • Dong Wang
  • Guangyu An
  • Shengzhi Xie
  • Yajuan Yao
  • Guosheng Feng
Original Article


Myeloid-derived suppressor cells (MDSCs) are key player in mediating systemic immunosuppression, and their accumulation and expansion in the periphery and tumor have been iteratively observed in patients with various types of cancer. It has been reported that CD14+HLA-DR−/low MDSCs are increased in hepatocellular carcinoma (HCC) patients; however, the clinical significance of MDSC alteration in HCC patients after treatment is poorly studied. In this study, we examined the frequency of MDSCs in 92 HCC patients, 14 chronic liver disease patients without HCC, and 22 healthy controls by flow cytometric analysis. The associations between the clinical features and the frequency of MDSCs were analyzed. In particular, we further examined the prognostic impact of MDSCs on the overall survival of HCC patients receiving radiation therapy. The frequency of MDSCs in HCC patients was significantly increased and correlated with tumor stage, size, burden, and Child-Pugh classification but not with biochemical parameters of liver function. In HCC patients who received radiation therapy, the frequency of MDSCs after treatment significantly decreased and was inversely correlated with overall survival time. In multivariate analysis, only post-treatment MDSC ratio and Child-Pugh classification were correlated with the prognosis of HCC patients. Patients with a high frequency of MDSCs after radiotherapy should be closely followed, and the inhibition of MDSCs may improve the prognosis of patients.


Myeloid-derived suppressor cells Hepatocellular carcinoma Radiation therapy Overall survival 



We thank Yang Yang for his excellent technical assistance in flow cytometry. This work was supported by the Beijing Natural Science Foundation (No. 7133253). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Compliance with ethical standards

The study protocol was approved by the Ethics Committee of Beijing Chao-Yang Hospital. All participants provided written informed consent.

Conflicts of interest



  1. 1.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRefPubMedGoogle Scholar
  2. 2.
    French SW, Lee J, Zhong J, Morgan TR, Buslon V, Lungo W, et al. Alcoholic liver disease—hepatocellular carcinoma transformation. J Gastrointest Oncol. 2012;3:174–81.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000;232:381–91.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist. 2010;15 Suppl 4:42–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Mizukoshi E, et al. Randomized, phase ii study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology. 2011;81:281–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Feng M, Ben-Josef E. Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol. 2011;21:271–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Izumi N, Asahina Y, Noguchi O, Uchihara M, Kanazawa N, Itakura J, et al. Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer. 2001;91:949–56.CrossRefPubMedGoogle Scholar
  8. 8.
    Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer. 2003;97:1253–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Butterfield LH. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology. 2004;127:S232–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine ima901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18:1254–61.CrossRefPubMedGoogle Scholar
  11. 11.
    Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer immunol Immunother. 2010;59:1593–600.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011;11:802–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces cd4(+)cd25(+)foxp3(+) T cells. Gastroenterology. 2008;135:234–43.CrossRefPubMedGoogle Scholar
  14. 14.
    Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T, et al. Increase in cd14+hla-dr−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother. 2013;62:1421–30.CrossRefPubMedGoogle Scholar
  15. 15.
    Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of garp(+)ctla-4(+)foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013;73:2435–44.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253–68.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Draghiciu O, Lubbers J, Nijman HW, Daemen T. Myeloid derived suppressor cells-an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunol. 2015;4:e954829.CrossRefGoogle Scholar
  18. 18.
    Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One. 2013;8:e57114.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011;118:2254–65.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499–506.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S, et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol. 2013;59:1007–13.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor gr+cd11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6:409–21.CrossRefPubMedGoogle Scholar
  24. 24.
    Waldron TJ, Quatromoni JG, Karakasheva TA, Singhal S, Rustgi AK. Myeloid derived suppressor cells: targets for therapy. Oncoimmunology. 2013;2:e24117.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al. Immunosuppressive cd14+hla-drlow/− monocytes in prostate cancer. Prostate. 2010;70:443–55.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Yuan XK, Zhao XK, Xia YC, Zhu X, Xiao P. Increased circulating immunosuppressive cd14(+)hla-dr(−/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J Int Med Res. 2011;39:1381–91.CrossRefPubMedGoogle Scholar
  27. 27.
    Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive cd14+hla-dr−/low cells in melanoma patients are stat3hi and overexpress cd80, cd83, and dc-sign. Cancer Res. 2010;70:4335–45.CrossRefPubMedGoogle Scholar
  28. 28.
    Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls t-lymphocyte functions. Trends Immunol. 2003;24:302–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Napolitano M, D’Alterio C, Cardone E, Trotta AM, Pecori B, Rega D, et al. Peripheral myeloid-derived suppressor and T regulatory pd-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. Oncotarget. 2015;6:8261–70.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Chen HM, Ma G, Gildener-Leapman N, Eisenstein S, Coakley BA, Ozao J, et al. Myeloid-derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy. Clin Cancer Res. 2015;21:4073–85.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60:1419–30.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11:239–53.CrossRefPubMedGoogle Scholar
  33. 33.
    Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med. 2013;5:173sr172.CrossRefGoogle Scholar
  34. 34.
    Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-pd-l1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–95.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Dong Wang
    • 1
    • 2
  • Guangyu An
    • 1
  • Shengzhi Xie
    • 3
  • Yajuan Yao
    • 2
  • Guosheng Feng
    • 1
  1. 1.Department of Oncology, Beijing Chao-Yang HospitalCapital Medical UniversityBeijingChina
  2. 2.Department of OncologyTong-Liao City Hospital of Inner MongoliaTong-LiaoChina
  3. 3.Department of OncologyGeneral Hospital of Chinese People’s Armed Police ForcesBeijingChina

Personalised recommendations